NewCo News: Beer Company Spinout ApoLife Launches Yeast-Based Pipeline
By Catherine Shaffer
Monday, October 10, 2011
ApoLife Inc. has joined the growing ranks of platform technology companies branching out into internal drug discovery and development. At a time when other small biotech companies are struggling to secure start-up financing, ApoLife already has a revenue stream from its yeast-based antibody production business.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.